Abstract

HERNANDEZ, DE; MARIN, ME  and  PEREZ, JR. Sarcoma de Kaposi Epidémico Avanzado: Beneficio Clínico con el régimen Doxorubicina-Bleomicina-Vincristina. RFM [online]. 2001, vol.24, n.2, pp.185-188. ISSN 0798-0469.

At present, the treatment of choice for patients with advanced epidemic Kaposi‘s sarcoma (EKS) is pegylated-liposomal doxorubicin (PLD); nevertheless, with doxorubicin (20 mg/m2)-bleomycin (10 mg/m2)-vincristine (1.4 mg/m2, maximun 2 mg) (ABV) regimen, every three weeks, clinical benefit can be obtained with low cost. Thirty, non-randomized patients, with advanced EKS, were treated with ABV. Between 60% to 100% of patients, obtained clinical benefits with 1 to 4 ABV cycles. Finally, patients with EKS obtain clinical benefits with ABV, and therefore it decreases morbidity and improves quality of life. Also, it is an acceptable alternative for patients with low financial resources who can not pay for PLD.

Keywords : Advanced Epidemic Kaposi’s Sarcoma; Trectment; ABV; Liposomar Doxorubicin (PLD).